Neuralstem's patent on neural stem cell transplantation approved

Neuralstem, Inc. (NYSE Amex: CUR) today announced that it has received notice of allowance from the United States Patent and Trademark Office (USPTO) for its patent entitled “Transplantation of Human Neural Cells For Treatment Of Neurodegenerative Conditions,” number 11/281,640.

“We are gratified to add this important core technology patent to our portfolio,” said Neuralstem President & CEO Richard Garr. “The transplantation of our neural stem cells to treat degenerative conditions of the nervous system is at the heart of Neuralstem’s mission.”

“Most importantly,” said Neuralstem Chief Scientific Officer, Dr. Karl Johe, “the claims in this patent cover the manufacturing process of our future products from all regions of the human central nervous system (brain and spinal cord) through July of 2026.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Stem cell transplant offers hope for patients with multiple sclerosis